Venomics AI, a biotechnology company spun out of the Indian Institute of Science (IISc) has raised US$2.7 million in its first institutional funding round. The pre-seed round was co-led by Speciale Invest and South Park Commons, with participation from Operators Studio.
The proceeds will be allocated for expansion, growing the molecular dataset, and strengthening its AI and laboratory screening capabilities, Venomics AI said in a press release.
Co-founded in May this year by Sunagar and Vinay Prabhu, Venomics AI is an IISc spin-out combining venom biology, molecular sequencing, AI and experimental screening to discover and develop venom-derived therapeutic leads., The company is building the Venom Atlas to connect venom-derived molecular data with laboratory validation and drug discovery.
The Bengaluru-based startup aims to investigate this diversity at scale. Its platform combines molecular sequencing and venom biology to build the Venom Atlas, uses AI to prioritise candidates, and tests those predictions through functional screening in the laboratory. Experimental results feed back into subsequent predictions and molecular design, connecting computational discovery with evidence of how molecules perform.
By combining India’s venom biodiversity with its scientific and computational expertise, Venomics AI aims to build a drug discovery platform in India for global therapeutic development. The company has established the initial architecture of its platform, joined the NVIDIA Inception programme, and been selected among the Top 5 finalists for the 2026 Indo-Boston Biotech Bridge Award.
It plans to build a multidisciplinary team across venom biology, computational science, and drug discovery, and support the validation and optimization of promising molecules.
Source link







